Zoledronic acid (also known as zoledronate) is a potent bisphosphonate medication used to treat diseases involving bone loss. It works by inhibiting osteoclast-mediated bone resorption, thereby increasing bone density and reducing the risk of fractures.
It is used to treat or prevent:
∙ Osteoporosis in postmenopausal women and men
∙ Paget’s disease of bone
∙ Bone complications from cancers (e.g., multiple myeloma, prostate, and breast cancer)
∙ Hypercalcemia of malignancy
∙ Glucocorticoid-induced osteoporosis
Zoledronic acid is typically administered as a once-yearly intravenous (IV) infusion for osteoporosis or more frequently in oncology settings.
Parent: ZOLEDRONIC ACID
Parent: Zoledronic Acid
Parent: Zoledronic Acid
Parent: Zoledronic Acid
Parent: Zoledronic Acid
Impurities in zoledronic acid can arise from the manufacturing process, degradation, or storage, and must be controlled according to ICH Q3A/B and pharmacopeial standards to ensure product safety and efficacy.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Zoledronic acid is used to:
Zoledronic acid:
Common side effects:
Serious but less common:
